HMGB1+  μPs purified from SSc patients, but not HMGB1−  μPs purified from control subjects, activate human leukocytes while HMGB1 inhibitors reverse the effects in vitro, suggesting that the moiety might be important in the maintenance of the SSc vascular inflammation [46]. The gene discussed is HMGB1; the disease is systemic sclerosis.